DSM-Firmenich's Solid CBD Formulation Matches Epidiolex's Bioavailability in Clinical Study
核心洞察
DSM-Firmenich (搜索)'s CBtru (搜索), a solid CBD formulation, demonstrates comparable absorption to Jazz Pharmaceuticals' liquid Epidiolex in a 32-person clinical trial, marking a significant breakthrough in CBD drug delivery.
The novel powder formulation achieves enhanced bioavailability and higher drug loading, potentially overcoming traditional CBD absorption challenges that typically limit bioavailability to as low as 6%.
The development opens new possibilities for oral solid dosage forms of CBD, offering patients more convenient alternatives to liquid formulations while maintaining consistent drug uptake regardless of food intake.
DSM-Firmenich (搜索) has achieved a significant breakthrough in cannabidiol (CBD) drug development, with their novel CBtru (搜索) formulation demonstrating blood absorption levels comparable to Jazz Pharmaceuticals' Epidiolex in a recent clinical study. This marks the first time a solid CBD formulation has matched the bioavailability of a liquid/oil-based reference product.
Clinical Study Details and Findings
The randomized clinical trial (NCT06578455) enrolled 32 participants, equally divided between men and women aged 19-55 years. The study compared 400 mg doses of CBtru (搜索) in capsule form against Epidiolex's liquid formulation under both fed and fasted conditions. Following a two-week washout period between administrations, researchers analyzed plasma concentrations over 24 hours post-treatment. Results indicated that CBtru provided consistent and reliable uptake with reduced dependence on food intake.
Technical Innovation in Formulation
CBtru (搜索)'s development addresses a fundamental challenge in CBD therapeutics - the compound's limited solubility and variable bioavailability, which typically hovers around 6% due to incomplete gut absorption and significant pre-systemic liver elimination. While Epidiolex utilizes a sesame oil-based formulation to enhance CBD absorption through lipid solubility, CBtru achieves comparable results in a solid powder form with higher drug loading capabilities.
Clinical Implications and Future Applications
Dr. Zdravka Misic, Associate Innovation Director at DSM-Firmenich (搜索), emphasized the broader implications: "This breakthrough could accelerate research in therapeutic areas where CBD has shown potential, such as pain management, inflammation, cancer (搜索), diabetes (搜索), as well as sleep, mood, and psychotic disorders."
The development of an effective solid formulation addresses key patient needs in CBD therapy. Oral solid dosage forms offer several advantages over liquid formulations, including:
- More accurate dosing capabilities
- Enhanced patient compliance
- Improved convenience in administration
- Better sensory experience compared to oil-based therapies
These benefits are particularly relevant for patients requiring CBD for treatment-resistant epileptic syndromes (搜索), where precise dosing and consistent absorption are crucial for therapeutic success.